At Upstream Bio we strive to reach the source of inflammation and conquer it.
Our lead program, verekitug, is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. We have completed Phase 1b in asthma and have initiated Phase 2 studies in both CRSwNP (chronic rhinosinusitis with nasal polyps) and asthma.
We are leveraging our diverse roots and the team’s substantial industry experience to develop verekitug to ease the burden of inflammatory and allergic diseases on patients and their loved ones.
